



Post Authorisation Assessments

Clavaseptin 750 mg Palatable Tablets for Dogs Vm 08007/3009

14 December 2024	Submission of updated CEP for an active substance manufacturer.
14 December 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
25 July 2023	Changes to the labelling of the finished product.
30 June 2023	Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product: - Change in the holding time of an intermediate or bulk product (if applicable).
24 March 2023	Minor changes to an approved test procedure the finished product.